After reinvigorating a decades-old schizophrenia drug in an innovative long-acting treatment option, Teva is looking to unlock its next chapter of mental health treatment. TEV’749 is a long ...

On December 17, Teva Pharmaceutical Industries Limited reported that duvakitug had shown stunning results in a phase 2b study for the treatment of Crohn's disease and ulcerative colitis.

Teva Pharmaceutical (NYSE:TEVA) shares rose for seven straight sessions, as the stock closed about 1% higher at $22.42 on Tuesday. The Israeli drugmaker stock added 34.5% in the preceding six ...

Learn more. For more information on how we test products, click here. The best summer fashion essentials for men are perfect for those balmy afternoons down at your local brewery with mates. However, ...

Teva also boasts a compelling growth trajectory, with revenue expected to increase by 15% and EBIT by 30% from 2024 to 2028. Free cash flow yield, currently at 9.8%, is projected to exceed 16% by ...